RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Contract Value
Not provided
Codes & Classification
Solicitation Number
75A50126R00002
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AB12
Additional Details
Documents2
The Office of the Assistant Secretary for Preparedness and Response (ASPR), through the Biomedical Advanced Research and Development Authority (BARDA), has issued a solicitation (Procurement Identifier: 75A50126R00002) seeking proposals for the late-stage clinical development and regulatory approval of 2-PAM autoinjectors. These autoinjectors, which are drug/device combination products, are intended for the treatment of organophosphate (OP) poisoning—including exposure to nerve agents—in both adult and pediatric populations. The procurement also encompasses the acquisition of 2-PAM autoinjectors for inclusion in the Strategic National Stockpile (SNS) and the CHEMPACK Program, which are critical components of the nation’s emergency preparedness infrastructure.
The scope of this procurement is comprehensive, requiring contractors to advance 2-PAM autoinjectors through late-stage clinical development, secure regulatory approval, and ensure the availability of these products for deployment in national emergency response programs. The intended outcome is to bolster the United States’ capacity to respond effectively to chemical threats by providing proven, ready-to-use medical countermeasures for OP poisoning.
Key requirements include demonstrated expertise in research and development in biotechnology (NAICS Code: 541714), with a focus on drug/device combination products. Contractors must be capable of supporting clinical trials, navigating regulatory pathways, and managing large-scale production and delivery of autoinjectors suitable for both adult and pediatric use. The expected deliverables are regulatory-approved 2-PAM autoinjectors, ready for procurement and integration into the SNS/CHEMPACK Program.
The contracting entity is BARDA, operating under the Department of Health and Human Services (HHS), specifically within the ASPR/DAAPPO/BARDA DCMA office. The place of performance is Washington, District of Columbia (DC), United States. The solicitation is classified under Product Service Code AB12, which pertains to research and development in biotechnology, excluding nanobiotechnology. There are no set-aside requirements for this procurement, making it open to all qualified entities.
Interested parties should note that the procurement is a solicitation, and the opportunity remains active. The primary point of contact is Erin Greninger, Contracting Officer ([email protected]), with Greg Smith as the secondary contact ([email protected]). The solicitation was posted on August 7, 2026, with responses due by July 30, 2026. Additional information, including attachments, can be accessed via the SAM.gov opportunity link: https://sam.gov/opp/fdeb92ea04f44edab955e76326567526/view.
Contractors evaluating this opportunity should ensure alignment with the technical, regulatory, and production requirements outlined, as well as the ability to support the government’s mission to enhance national preparedness against chemical threats. The elements described herein are expected to remain constant throughout the contract lifecycle, focusing on the development, approval, and procurement of 2-PAM autoinjectors for emergency medical use.